Azimuth Capital Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Azimuth Capital Management’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-20,375	Closed	-$1.65M	–	287
2018 Q1	$1.65M	Buy	20,375 +2,470	+14%	+$200K	0.12%	172
2017 Q4	$1.41M	Sell	17,905 -4,005	-18%	-$333K	0.1%	184
2017 Q3	$2.02M	Sell	21,910 -6,475	-23%	-$622K	0.15%	166
2017 Q2	$3.21M	Buy	28,385 +330	+1%	+$36.9K	0.25%	139
2017 Q1	$2.81M	Buy	28,055 +1,660	+6%	+$177K	0.23%	144
2016 Q4	$2.84M	Buy	26,395 +335	+1%	+$39.2K	0.24%	139
2016 Q3	$3.24M	Buy	+26,060	New	+$3.08M	0.28%	115

Other funds holding CBPO

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Azimuth Capital Management's CBPO Position: Q2 2018 in Review

Azimuth Capital Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2018, closing a stake of 20,375 shares — an estimated $1.65M sold.

Azimuth Capital Management first reported a position in CBPO in Q3 2016 and held it in 7 quarters. The position peaked at $3.24M in Q3 2016. 91 funds tracked by Wall St. Rank hold CBPO as of Q2 2018.

Azimuth Capital Management reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2018 after selling out during the quarter.
Azimuth Capital Management sold 20,375 China Biologic Products Holdings, Inc. shares in Q2 2018, an estimated $1.65M.
Azimuth Capital Management first reported a position in China Biologic Products Holdings, Inc. in Q3 2016 and held it in 7 quarters.
Azimuth Capital Management's China Biologic Products Holdings, Inc. position peaked at $3.24M in Q3 2016.
91 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2018.

Based on Azimuth Capital Management's 13F filing for Q2 2018, filed 10 Aug 2018.